Rodman & Renshaw Begins Coverage on SAB Biotherapeutics (NASDAQ:SABS)

Stock analysts at Rodman & Renshaw began coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm set a “buy” rating and a $13.00 price target on the stock. Rodman & Renshaw’s price target points to a potential upside of 235.05% from the stock’s previous close.

Several other research firms also recently weighed in on SABS. HC Wainwright dropped their target price on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. Zacks Research lowered shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 12th. Guggenheim began coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They set a “buy” rating and a $15.00 price objective for the company. Chardan Capital lifted their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, UBS Group initiated coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.50.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.88 on Thursday. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The firm has a market capitalization of $197.69 million, a price-to-earnings ratio of -1.67 and a beta of 0.60. The stock’s fifty day moving average is $4.01 and its two-hundred day moving average is $3.54. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC acquired a new position in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $3,004,000. Millennium Management LLC acquired a new stake in SAB Biotherapeutics during the fourth quarter worth approximately $1,212,000. Balyasny Asset Management L.P. purchased a new stake in SAB Biotherapeutics in the 4th quarter worth approximately $1,778,000. ADAR1 Capital Management LLC grew its stake in SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after acquiring an additional 11,344 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new position in SAB Biotherapeutics in the 4th quarter valued at $322,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.